AI assistant
Biohit Oyj — Director's Dealing 2017
Feb 23, 2017
3304_rns_2017-02-23_3bb49caf-8ecc-44d5-ae00-55e067be87b6.html
Director's Dealing
Open in viewerOpens in your device viewer
Biohit Oyj - Managers' Transactions
Biohit Oyj - Managers' Transactions
Biohit Oyj - Managers' Transactions, February 23, 2017 at 3:55 pm local time
(EET)
____________________________________________
Person subject to the notification requirement
Name: Korpela, Semi
Position: Chief Executive Officer
Issuer: Biohit Oyj
LEI: 74370089ATTSNBXJVT29
Notification type: INITIAL NOTIFICATION
Reference number: 74370089ATTSNBXJVT29_20170223130523_7
____________________________________________
Transaction date: 2017-02-20
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
ISIN: FI4000219324
Nature of the transaction: SUBSCRIPTION
(X) Linked to stock option programme
Transaction Details
(1): Volume: 9810 Unit price: 2,27660 EUR
(2): Volume: 1280 Unit price: 2,27660 EUR
Aggregated transactions
(2): Volume: 11090 Volume weighted average price: 2.27660 EUR
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
[email protected]
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s
mission is “Innovating for Health” – we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B
share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.
www.biohithealthcare.com